GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for IVVE

IVVE

Official Title

A Randomized Trial of Influenza Vaccine to Prevent Adverse Vascular Events

Status

Ongoing

Overview

Evidence exists that influenza increases adverse vascular events. However whether influenza vaccination can reduce adverse vascular events remains controversial. The goal of this study is to randomize patients with heart failure to either inactivated influenza vaccine or to placebo to assess whether influenza vaccine can reduce adverse vascular events.

 

Study Design

The IVVE study is a multi-centre, randomized, placebo controlled trial.

Primary Endpoint

The primary endpoint is a composite of cardiovascular death, non-fatal myocardial infarction, non-fata stroke and hospitalizations for heart failure.

Number of Patients

3500

Number of Sites

27

Number of Countries

11

Study Period

2015-2020

Principal Investigator

Mark Loeb, Hisham Dokainish

Research Coordinator

Alex Grinvalds

Collaborators

McMaster University